Actively Recruiting

Phase 3
Age: 18Years - 85Years
All Genders
NCT07208591

To Evaluate The Safety and Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome

Led by Staidson (Beijing) Biopharmaceuticals Co., Ltd · Updated on 2026-01-02

406

Participants Needed

15

Research Sites

47 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

To evaluate the efficacy, safety and tolerability of STSA-1002 injection in patients with acute respiratory distress syndrome

CONDITIONS

Official Title

To Evaluate The Safety and Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome

Who Can Participate

Age: 18Years - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 18 and 85 years old
  • Laboratory tests confirm respiratory viral infection
  • Meet diagnostic criteria for acute respiratory distress syndrome
  • Symptoms started within 12 days before randomization for patients without mechanical ventilation
  • Symptoms started within 14 days before randomization for patients with invasive mechanical ventilation
  • Worsening respiratory symptoms within 7 days from randomization
  • PaO2/FiO2 ratio less than or equal to 200 mmHg
  • Agree to use effective contraception during the trial and for 3 months after last dose
  • Willing to volunteer and sign informed consent form
Not Eligible

You will not qualify if you...

  • Receiving ECMO before first dose
  • Condition improved within 48 hours before first dose
  • Expected survival less than 24 hours or cardiac arrest in past 4 weeks
  • Stroke or acute coronary syndrome within 3 months before randomization
  • Cardiogenic pulmonary edema causing respiratory failure; New York Heart Class III-IV
  • Severe chronic respiratory failure
  • Active pulmonary tuberculosis
  • Liver insufficiency
  • Long-term dialysis or severe renal impairment
  • Cytomegalovirus infection
  • HIV infection with low CD4 count (<200 cells/µL)
  • Organ transplant recipient
  • Radiotherapy or chemotherapy in past 1 year or active cancer
  • Septic shock
  • Absolute neutrophil count less than 0.5x10^9/L
  • Hemoglobin less than 60 g/L or active gastrointestinal bleeding
  • Severe underlying diseases affecting treatment compliance
  • Pregnant or lactating women
  • Participated in other drug trials or medication in past 3 months
  • Allergic to trial drug or its components
  • Other conditions deemed unsuitable by investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 15 locations

1

China-Japan Friendship Hospital

Beijing, Beijing Municipality, China, 100029

Actively Recruiting

2

The First Affiliated Hospital of Xiamen University

Xiamen, Fujian, China, 361003

Actively Recruiting

3

The Third Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China, 510150

Actively Recruiting

4

The First Affiliated Hospital, Sun Yat-sen University

Guangzhou, Guangdong, China, 51063

Actively Recruiting

5

The Affiliated Hospital of Zunyi Medical University

Zunyi, Guizhou, China, 563000

Actively Recruiting

6

The First Affiliated Hospital of Henan University of Science and Technology

Luoyang, Henan, China, 471099

Actively Recruiting

7

Henan Provincial People's Hospital

Zhengzhou, Henan, China, 450003

Actively Recruiting

8

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China, 450052

Actively Recruiting

9

Wuhan Central Hospital

Wuhan, Hubei, China, 430014

Actively Recruiting

10

Xiangtan Central Hospital

Xiangtan, Hunan, China, 411100

Actively Recruiting

11

The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China, 330006

Actively Recruiting

12

Weifang People's Hospital

Weifang, Shandong, China, 261041

Actively Recruiting

13

Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital

Chengdu, Sichuan, China, 610072

Actively Recruiting

14

Dazhou Central Hospital

Dazhou, Sichuan, China, 635099

Actively Recruiting

15

Hangzhou First People's Hospital

Hangzhou, Zhejiang, China, 310006

Actively Recruiting

Loading map...

Research Team

A

Aiping Sun

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here